Capricor Therapeutics, J&J deal

Capricor partnered with Johnson & Johnson's Janssen Biotech Inc. subsidiary to develop Capricor's cell therapy programs for cardiologic applications, including Capricor's lead program, CAP-1002. Capricor, which will receive $12.5 million up front, retains rights to its programs for vascular indications. CEO Linda Marban said specific responsibilities have not yet been determined, though she told BioCentury the partners are initially going to focus on developing a manufacturing process for CAP-1002. Capricor will contribute undisclosed, capped funding for manufacturing costs. ...